More details of PF-03187207 clinical trial revealed
In a follow up to a story covered in the Marketletter on March 28, French biopharmaceutical company NicOx SA says that US drug major Pfizer has provided additional details regarding the first clinical trial of PF-03187207 in the treatment of glaucoma and ocular hypertension. The French firm made the original announcement after Pfizer's initiation of the clinical trial resulted in a milestone payment of 1.0 million euros ($1.3 million).
NicOX explained that the Phase II dose-ranging assessment is designed to compare the safety and efficacy of the agent to latanoprost, in patients with open angle glaucoma or ocular hypertension in one or both eyes. The program will run for 28 days, and will measure the compound's impact on diurnal intraocular pressure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze